Aiolos Bio: GSK Pays $1.4 Billion to Acquire Aiolos, which In-Licensed a Hengrui Asthma Candidate

GSK plans to acquire Aiolos Bio, a San Francisco-London startup, for $1 billion upfront and up to $400 million in regulatory milestones. Aiolos' major asset is AIO-001, a long-acting mAb for asthma in Phase II trials. In August, Aiolos acquired global ex-China rights to the candidate from Jiangsu Hengrui Medicine (SHA: 600275) for $21.5 million upfront and over $1 billion in milestones plus royalties. AIO-001 targets the thymic stromal lymphopoietin (TSLP) cytokine, a driver of inflammation. Aiolos expects AIO-001 to require dosing only every six months. More details....Share this with colleagues: